Form 4: Cormorant Funds Divest MLTX Shares

Cormorant Asset Management and affiliated funds reported significant sales of MoonLake Immunotherapeutics Class A Ordinary Shares across multiple transactions in late September 2025.

Summary

• Cormorant Asset Management, LP, along with its affiliated funds (Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare Fund IV, LP, and a managed account), reported multiple sales of MoonLake Immunotherapeutics (MLTX) Class A Ordinary Shares.
• On September 29, 2025, a total of 6,494,151 shares were sold in four separate transactions at weighted average prices ranging from $6.61 to $9.38 per share.
• An additional 5,827 shares were sold on September 30, 2025, at a weighted average price of $6.96 per share.
• Following these transactions, the reporting persons collectively beneficially own 1,994,173 Class A Ordinary Shares indirectly.
• The reporting persons, including Bihua Chen, are identified as former 10% owners of MoonLake Immunotherapeutics.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant divestment by a major institutional investor and former 10% owner, which can signal a lack of confidence in the company's future prospects. The declining sale prices during the transaction period further contribute to this negative sentiment.

Positives

• The transactions were executed at varying price points, indicating a structured approach to divestment rather than a single distressed sale.
• The reporting persons undertake to provide full information regarding the number of shares sold at each price upon request, demonstrating transparency.

Negatives

• Significant divestment by a former 10% owner and associated funds could signal a loss of confidence or a strategic portfolio reallocation away from MoonLake Immunotherapeutics.
• The sales occurred over a period where the weighted average price per share generally declined from $9.38 to $6.61 on September 29, 2025, before a slight rebound to $6.96 on September 30, 2025, potentially indicating selling into a weakening market.
• The reporting persons are now 'Former 10% Owners,' indicating a substantial reduction in their stake and influence.

Risks

• Large-scale selling by institutional investors can exert downward pressure on the stock price.
• A significant reduction in ownership by a major investor might be interpreted by the market as a negative signal regarding the company's future prospects or valuation.

Future Outlook

NA

Industry Context

This filing reflects a significant divestment by a major institutional investor in the biotechnology sector. Such sales can sometimes precede or coincide with shifts in investor sentiment towards specific companies or the broader industry, particularly if the company's pipeline or market position faces new challenges or opportunities. Without additional context on MoonLake Immunotherapeutics' specific developments, it is difficult to ascertain the precise industry implications, but large sales by informed investors are often closely watched.

Stakeholder Impact

• Shareholders: Potential negative impact due to increased selling pressure and a possible signal of reduced institutional confidence, which could lead to a decrease in share price.
• Company Management: May face questions regarding the reasons for a major investor's divestment and its implications for future capital raising or strategic partnerships.

Key Dates

Recommendation

The significant divestment by a former 10% owner and associated institutional funds, totaling over 6.5 million shares, indicates a strong negative signal from a sophisticated investor. The sales occurring at generally declining prices further reinforce a bearish outlook. This action suggests that a major holder has lost conviction or is strategically reallocating capital away from MoonLake Immunotherapeutics, which could exert downward pressure on the stock. Investors should consider this substantial insider selling as a potential indicator of future underperformance or a re-evaluation of the company's fundamentals by informed market participants.

Keywords

MoonLake Immunotherapeutics, MLTX, Cormorant Asset Management, Insider Selling, Form 4, Beneficial Ownership, Share Sale, Institutional Investor, Biotechnology, Healthcare